Description: Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company offers its drug discovery services using its structure-based drug discovery, fragment-based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. It offers gene-to-protein and gene-to-structure, viva engine for lead discovery, membrane protein targeted discovery technology, medicinal chemistry, in vitro pharmacology, and antibody discovery services. The company primarily develops cell lines, crystal structures, GPCR proteins, antibodies, and proteins. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.
Home Page: www.vivabiotech.com.cn
No.735, Ziping Road
Shanghai,
201318
China
Phone:
86 21 6089 3288
Officers
| Name | Title |
|---|---|
| Dr. Chen Cheney Mao Ph.D. | Chairman & CEO |
| Mr. Ying Wu M.B.A. | Executive VP & Executive Director |
| Dr. Delin Ren Ph.D. | Executive Director |
| Mr. Wei Xiong | Chief Financial Officer |
| Mr. Xueheng Cheng Ph.D. | Chief Technology Officer |
| Dr. Zhixiong Ye Ph.D. | Chief Scientific Officer |
| Mr. Han Dai Ph.D. | Chief Innovation Officer & Head of Viva BioInnovator |
| Mr. Jianhua Cai Ph.D. | Senior Vice President |
| Jianguo Ma Ph.D. | Senior VP & President of Shanghai Langhua Pharmaceutical |
| Mr. Xianyong Bu Ph.D. | CBO & EVP of Viva Biotech (Shanghai) |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4738 |
| Price-to-Sales TTM: | 0.1282 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2043 |